Newsletter SignupSearch

Secondary Analysis of PTSD Genome Wide Association Study Data Published in Cell Reports

Cohen Veterans Bioscience is proud to co-fund this study which is a secondary analysis of the data from our 2019 Post-Traumatic Stress Disorder (PTSD) Genome Wide Association Study to better understand how the expression of certain genes may affect vulnerability to PTSD and may provide insights for prevention and treatment.

Cohen Veterans Bioscience is proud to co-fund this study which is a secondary analysis of the data from our 2019 Post-Traumatic Stress Disorder (PTSD) Genome Wide Association Study to better understand how the expression of certain genes may affect vulnerability to PTSD and may provide insights for prevention and treatment.

In the face of repeated, prolonged, or severe trauma, some individuals seem to be more susceptible to PTSD while others are resilient. Identifying which individuals may be susceptible to PTSD‚ and why, can help researchers develop effective interventions.

Read the study in Cell Reports and learn more here.

Share this article:

More from CVB

American Brain Coalition Selects Cohen Veterans Bioscience Executive as New Board Member

New Artificial-Intelligence-based Tools for Monitoring Parkinson’s Disease using Wearable Devices

Peter Hoehn, Accomplished Pharmaceutical Executive, Joins Cohen Veterans Bioscience (CVB) in Newly Created Executive Leadership Role

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.